MSN Laboratories

What MSN Laboratories does

MSN Laboratories Pvt. Ltd. (MSN Labs) is an Indian pharmaceutical manufacturer and CDMO founded in 2003 (with some sources citing 2006) and headquartered in Hyderabad, Telangana. The company operates three integrated business lines: (1) API manufacturing through 17 dedicated facilities, delivering one of the world's largest API portfolios across diverse therapies; (2) Formulations, encompassing 400+ finished dosage products including 200+ first-to-market generics spanning oncology, cardiovascular, pulmonary arterial hypertension, diabetes, CNS, anti-infectives, and pain management; and (3) CRAMS (Contract Research and Manufacturing Services) providing end-to-end development and large-scale manufacturing partnerships to global pharmaceutical companies. Notable flagship products include Semabest (generic semaglutide, launched April 2026 in India at ~50% below innovator pricing) and Bosutinib Tablets 400mg (developed for Dr. Reddy's US launch in June 2026 with 180-day generic exclusivity against a $253.8M reference market).

The company is privately held and founder-controlled under Chairman Dr. MSN Reddy as part of the MSN Group of Companies, with 10,000+ employees and a wholly-owned subsidiary network spanning India, CIS (Kazakhstan, Uzbekistan, Georgia), LATAM (Panama, Jamaica, Brazil, Mexico, Colombia, Peru, Chile, Dominican Republic, Ecuador), North America (USA, Canada), Europe (Poland, Malta, Czech Republic via Vivanta Generics, Germany), MENA (UAE, Saudi Arabia), and Africa (Kenya, South Africa, Nigeria and 13+ additional countries). MSN generates revenue through generic pharmaceutical sales to distribution partners, direct B2B sales through regional subsidiaries, and contract manufacturing partnerships. The company competes on a 30-40% cost advantage versus Western CDMOs and pursues an active Paragraph IV patent challenge strategy in the US market. AI/ML capabilities are not disclosed in available materials.

Name

MSN Laboratories

Legal name

MSN Laboratories Pvt.Ltd.

Website

https://msnlabs.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

MSN Laboratories is an Indian pharmaceutical CDMO and generic drug manufacturer operating 17 API facilities and 400+ formulations, serving global pharma companies, distribution partners, and patients across Asia, LATAM, CIS, Europe, MENA, Africa, and North America.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Generic pharmaceuticals
• API manufacturing
• Contract manufacturing services
• Pharmaceutical formulations
• CDMO services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices13 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: MSN Laboratories generates revenue through development and manufacturing of generic pharmaceutical products including APIs and finished dosage formulations. Revenue comes from product sales to distribution partners and contract manufacturing services.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

MSN Laboratories develops, manufactures, and commercializes generic pharmaceutical products across active pharmaceutical ingredients (APIs) and finished formulations, alongside offering end-to-end Contract Research and Manufacturing Services (CRAMS) to global pharmaceutical partners. The company operates 17 API facilities, delivers 400+ formulations including 200+ first-to-market generics, and serves therapeutic areas including oncology, cardiovascular, pulmonary, metabolic, CNS, pain, and anti-infectives.

Product overview

MSN Laboratories is a pharmaceutical company offering a comprehensive portfolio of pharmaceutical products and services organized across three core divisions: (1) APIs manufactured through 17 dedicated facilities, (2) Formulations encompassing 400+ products including 200+ first-to-market generics, and (3) CRAMS (Contract Research and Manufacturing Services) providing end-to-end development and manufacturing partnerships. Key therapeutic areas include oncology (Bosutinib, Abiraterone, Cabozantinib, Tucatinib, Bortezomib, Clofarabine), cardiovascular/pulmonary (Bosentan, Ambrisentan, Macitentan, Sildenafil, Ticagrelor, Eplerenone), metabolic/diabetes (Semaglutide/Semabest, Empagliflozin, Dapaglutide, Vildagliptin, Febuxostat), CNS/pain (Tapentadol, Levetiracetam, Brivaracetam), and anti-infectives (Remdesivir, Favipiravir, Posaconazole). The company operates through regional subsidiaries including Vivanta Generics (Europe) and maintains commercial presence across Asia, Latin America, CIS, North America, MENA, and Africa regions. MSN collaborates with Dr. Reddy's on select products, notably Bosutinib Tablets 400mg for the US market.

Differentiator

Problem solved

Functional benefit

Brands

• Vivanta Generics: European subsidiary focused on delivering safe and effective generic medicines across Europe, part of MSN group of companies

Products and services

• Active Pharmaceutical Ingredients (APIs) Bulk active pharmaceutical ingredients manufactured across 17 facilities for diverse therapeutic areas including oncology, cardiovascular, pulmonary, metabolic, CNS, pain, and anti-infectives. Sold to pharmaceutical companies globally.
• Generic Pharmaceutical Formulations 400+ finished dosage formulations covering cardiovascular, oncology, pulmonary, metabolic/diabetes, CNS/pain, and anti-infective therapeutic areas, including 200+ first-to-market generics. Sold through distribution networks and subsidiaries across global markets.
• CRAMS (Contract Research and Manufacturing Services) End-to-end contract research and manufacturing services for global pharmaceutical partners, from API/formulation development to large-scale commercial supply. Includes exclusive marketing licensing arrangements (e.g., Dr. Reddy's holding exclusive US marketing rights for MSN-developed products like Bosutinib).
• Semabest (Generic Semaglutide) Generic semaglutide GLP-1 receptor agonist for type 2 diabetes and weight management, available as a pre-filled pen for subcutaneous administration in 2mg, 4mg, and 8mg dosages. Priced approximately 50% lower than innovator product in India.
• Bosutinib Tablets 400mg Generic equivalent of Pfizer's Bosulif used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML). Developed and manufactured by MSN Laboratories, with Dr. Reddy's holding exclusive US marketing rights. First-to-market launch with 180-day generic exclusivity.
• Vivanta Generics European Portfolio European-focused generic medicines portfolio covering cardiovascular, metabolic, neurological, and oncology conditions, distributed across European markets through Vivanta Generics offices in Czech Republic, Poland, Malta, and Germany.

Quantifiable outcome

• Semaglutide (Semabest) priced 50% lower than innovator product, with MRP ranging from ₹3990 to ₹5490
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Dr. Reddy's LaboratoriescoreStrategic or Co-development Partner · 13 June 2026MSN Laboratories developed and manufactured Bosutinib Tablets 400mg (generic equivalent of Pfizer's Bosulif) while Dr. Reddy's holds exclusive US marketing rights. The collaboration resulted in first-to-market launch with 180-day generic exclusivity. The product is used to treat Philadelphia chromosome-positive chronic myeloid leukaemia, with the reference brand recording approximately $253.8 million in US sales for the 12-month period ended April 2026.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cipla: Indian pharma major with global generics, API and respiratory/injectables focus — closely comparable to MSN across therapeutic breadth, emerging-market presence and CDMO/contract manufacturing services.
• Glenmark Pharmaceuticals: Indian-headquartered pharma with generics, APIs and innovative R&D pipeline — comparable to MSN on emerging-market distribution, complex generics focus and global subsidiary footprint.
• Lupin: Indian generic pharma and API manufacturer with US-focused complex generics and biosimilars pipeline — comparable to MSN on API-to-formulation integration, complex generic strategy and global regulatory footprint.
• Zydus Lifesciences (Cadila Healthcare): Indian integrated pharma with APIs, formulations, biosimilars and consumer healthcare — directly comparable to MSN on diversified pharma model and US specialty generic ambitions.
• Dr. Reddy's Laboratories: Indian integrated pharma with global generics, API and CDMO operations; strategic partner of MSN for Bosutinib US launch — directly comparable across product portfolio, regulated market exposure and CRAMS scale.
• Sun Pharmaceutical Industries: India's largest pharma company with extensive specialty generics, API and formulation footprint — comparable to MSN on scale, therapeutic breadth, global subsidiary network and USFDA-registered facility base.
• Aurobindo Pharma: Large Indian generic pharmaceutical and API manufacturer with global presence across formulations, APIs and biosimilars — directly comparable to MSN's API/formulation/CRAMS model and similar cost-arbitrage positioning.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars division of Novartis — broader incumbent comparable to MSN's generics/biologics ambitions and serves as both competitor and potential strategic partner for MSN-developed products.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep US presence and broad portfolio — broader incumbent that competes head-to-head with MSN on US generics and APIs while operating at much larger scale.
• Apotex: Canadian-headquartered generic pharma with significant API manufacturing and CDMO services — comparable to MSN on integrated API/formulation model and North American generic distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/MSNLabs
• LinkedInlinkedin.com/company/msnlabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSN Laboratories